Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Director departure
CC transcript
IMMUCOR INC (BLUD) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/18/2017 8-K Quarterly results
06/23/2017 8-K Form 8-K - Current report
06/21/2017 8-K Form 8-K - Current report
06/19/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "IMMUCOR, INC. ANNOUNCES"
04/19/2017 8-K Form 8-K - Current report
05/10/2016 8-K Form 8-K - Current report
12/15/2015 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amendment No. 5 to the Credit Agreement"
07/13/2015 8-K Resignation/termination of a director
07/02/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Jeffrey R. Binder Appointed President and CEO of Immucor Norcross, Georgia – June 29, 2015– Immucor, Inc., a global leader in transfusion and transplantation diagnostics and a portfolio company of global private investment firm TPG, today announced the appointment of Jeffrey R. Binder as President, Chief Executive Officer and Chairman of the Board of Directors. Binder succeeds CEO William A. Hawkins III , who now assumes the role of Lead Director on the Immucor Board of Directors. Binder, a 22-year veteran of the healthcare industry, has proven experience in helping companies realize growth opportunities. Prior to joining Immucor, Binder was the President and CEO of Biomet, a leading designer, manufacturer and marketer of surgical and non-surgical products used primarily by orthopedic surg..."
06/03/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Immucor Announces Lifting of FDA NOIR NORCROSS, Ga., June 2, 2014 – Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that the U.S. Food and Drug Administration has informed the Company that the Notice of Intent to Revoke has been lifted. “We take our commitment to quality very seriously,” stated William A. Hawkins, Immucor’s President and Chief Executive Officer. “The core of Immucor’s business is making sure that patients who need a blood transfusion are matched with the right donor unit. Our upmost concern is delivering quality products so patients receive the life-saving transfusions they need.” The NOIR, which was issued by the FDA in June 2009, was related to the Company’s Reagent Red Blood Cells and Anti-E Blood Grouping Reagent products ..."
08/12/2013 8-K Form 8-K - Current report
03/22/2013 8-K Form 8-K - Current report
02/22/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amended and Restated Amendment No. 2 to Amended and Restated Credit Agreement, by and among Immucor, Inc., IVD Intermediate Holdings B Inc., the Subsidiary Guarantor party thereto, CitiBank, N.A., as administrative agent, and certain other parties thereto (the “Credit Agreement”)",
"Amendment No. 3 to the Credit Agreement",
"Amendment No. 4 to the Credit Agreement"
01/31/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amendment No. 2 to Amended and Restated Credit Agreement, by and among Immucor, Inc., IVD Intermediate Holdings B Inc., the Subsidiary Guarantor party thereto, CitiBank, N.A., as administrative agent, and certain other parties thereto"
01/16/2013 8-K Form 8-K - Current report
01/09/2013 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Stock Purchase Agreement by and between the Company and Gen-Probe Incorporated dated as of January 3, 2013*†",
"Financing and Advisors Immucor expects to fund the transaction through a combination of debt and equity. Fully committed financing has been secured from Citi Global Markets, Inc. and JPMorgan Chase Bank, N.A. Ropes and Gray LLP is representing Immucor in the transaction. Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories, and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of products for all of its market segments, including two fully automated instruments for serology testing – NEO® and Echo® – and its BioArray™ molecular BeadChip™ offering, which is CE marked in Europe and available on a resea..."
08/24/2012 8-K Form 8-K - Current report
02/27/2012 8-K Form 8-K - Current report
08/25/2011 8-K Form 8-K - Current report
08/16/2011 8-K Form 8-K - Current report
08/04/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE EXPIRATION OF HSR WAITING PERIOD",
"IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE GERMAN ANTITRUST AND MERGER CONTROL CLEARANCE"
07/15/2011 8-K Form 8-K - Current report
07/11/2011 8-K Form 8-K - Current report
07/05/2011 8-K Form 8-K - Current report
07/05/2011 8-K Form 8-K - Current report
06/15/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FY 2012 Bonus and Long-Term Incentive Plan for Executive Officers",
"FY 2012 Bonus and Long-Term Incentive Plan for Executive Officers",
"Amended and Restated Employment Agreement, by and between the Company and Richard A. Flynt",
"Amended and Restated Employment Agreement, by and between the Company and Richard A. Flynt",
"Amended and Restated Employment Agreement, by and between the Company and Philip H. Moïse",
"Amended and Restated Employment Agreement, by and between the Company and Philip H. Moïse"
06/13/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between the Company and Joshua H. Levine",
"Employment Agreement, by and between the Company and Joshua H. Levine",
"Indemnification Agreement, by and between the Company and Joshua H. Levine",
"Indemnification Agreement, by and between the Company and Joshua H. Levine",
"Immucor CEO Dr. Gioacchino De Chirico Announces Retirement; Board Appoints Joshua H. Levine CEO and Director",
"Immucor CEO Dr. Gioacchino De Chirico Announces Retirement; Board Appoints Joshua H. Levine CEO and Director"
04/14/2011 8-K Form 8-K - Current report
04/06/2011 8-K Form 8-K - Current report
01/06/2011 8-K Form 8-K - Current report
11/29/2010 8-K Form 8-K - Current report
11/16/2010 8-K Form 8-K - Current report
11/08/2010 8-K Form 8-K - Current report
10/26/2010 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy